Evaluate the Safety and Efficacy of FG-3019 in Patients With Idiopathic Pulmonary Fibrosis



Status:Completed
Conditions:Pulmonary
Therapuetic Areas:Pulmonary / Respiratory Diseases
Healthy:No
Age Range:40 - 80
Updated:2/17/2019
Start Date:June 2013
End Date:November 16, 2017

Use our guide to learn which trials are right for you!

A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of FG-3019 in Patients With Idiopathic Pulmonary Fibrosis

To evaluate the safety and tolerability of FG-3019 in subjects with IPF, and the efficacy of
FG-3019 in slowing the loss of forced vital capacity (FVC) and the progression of IPF in
these subjects.

The study has been amended accordingly in February 2016 to further allow for the enrollment
of a subgroup of subjects (N=60) who will be allowed to receive treatment with approved IPF
therapy with pirfenidone or with nintedanib as background therapy.

These additional subjects will be stratified by background therapy, randomized to FG-3019 or
placebo and followed up for 24 weeks. The main objective of the study remains safety. PK
samples to assess drug concentrations will also be collected.

(This substudy portion only applies to US and Canadian centers.)

Enrollment for the main study was completed on 29Jun2016 Enrollment for the sub-study was
completed on 16Dec2016

Inclusion Criteria:

1. Age 40 to 80 years, inclusive.

2. Diagnosis of IPF as defined by current international guidelines (Raghu, 2011). Each
subject must have one of the following: (1) Usual Interstitial Pneumonia (UIP) Pattern
on an available HRCT scan; or (2) Possible UIP Pattern on an available HRCT scan and
surgical lung biopsy within 4 years of Screening showing UIP Pattern.

3. History of IPF of ≤5 years duration with onset defined as the date of the first
diagnosis of IPF by HRCT or surgical lung biopsy.

4. Interstitial pulmonary fibrosis defined by HRCT scan at Screening, with evidence of
≥10% to <50% parenchymal fibrosis (reticulation) and <25% honeycombing, within the
whole lung, as determined by the HRCT central reader.

5. FVC percent of predicted value ≥55% at Screening.

6. Female subjects of childbearing potential (including those <1 year postmenopausal)
must be willing to use a medically acceptable method of contraception, for example, an
oral contraceptive, depot progesterone, or intrauterine device. Male subjects with
female partners of childbearing potential who are not using birth control as described
above must use a barrier method of contraception (e.g., condom) if not surgically
sterile (i.e., vasectomy).

7. All subjects in Arm A whose FVC percent predicted value is greater than the original
pre-treatment baseline in the Randomized Treatment Period will be offered
participation in an Extended Treatment Period

8. All subjects assigned to Placebo (Arm B) will be offered participation in the Extended
Treatment Phase.

9. For Substudy only: Receiving treatment for IPF with a stable dose of pirfenidone or
with a stable dose of nintedanib for at least 3 months before screening initiation and
willing to continue treatment with pirfenidone or with nintedanib according to the
corresponding approved label and the prescribing physician, including all listed
safety requirements (e.g., liver function tests, avoidance of sunlight and sunlamp
exposure and wearing of sunscreen and protective clothing daily for pirfenidone, and
smoking cessation).

Exclusion Criteria:

1. Women who are pregnant or nursing.

2. Infiltrative lung disease other than IPF, including any of the other types of
idiopathic interstitial pneumonias (Travis, 2013); lung diseases related to exposure
to fibrogenic agents or other environmental toxins or drugs; other types of
occupational lung diseases; granulomatous lung diseases; pulmonary vascular diseases;
systemic diseases, including vasculitis and connective tissue diseases.

3. HRCT scan findings at Screening are inconsistent with UIP Pattern, as determined by
the HRCT central reader.

4. Pathology diagnosis on surgical lung biopsy is anything other than UIP Pattern, as
determined by the local pathologist.

5. The Investigator judges that there has been sustained improvement in the severity of
IPF during the 12 months prior to Screening, based on changes in FVC, diffusing
capacity of the lung for carbon monoxide (DLCO), and/or HRCT scans of the chest.

6. Clinically important abnormal laboratory tests.

7. Upper or lower respiratory tract infection of any type within 4 weeks of the first
screening visit.

8. Acute exacerbation of IPF within 3 months of the first screening visit.

9. Use of medications to treat IPF within 5 half-lives of Day 1 dosing. If monoclonal
antibodies were used, the last dose of the antibody must be at least 4 weeks before
Day 1 dosing. This applies to subject enrolled in Main Study only.

10. Use of any investigational drugs, including any investigational drugs for IPF, within
4 weeks prior to Day 1 dosing.

11. History of cancer diagnosis of any type in the 3 years preceding Screening, excluding
non-melanomatous skin cancer, localized bladder cancer, or in situ cancers

12. Diffusing capacity (DLCO) less than 30% of predicted value

13. History of allergic or anaphylactic reaction to human, humanized, chimeric or murine
monoclonal antibodies.

14. Previous treatment with FG-3019.

15. Body weight greater than 130 kilograms.
We found this trial at
27
sites
201 Dowman Dr
Atlanta, Georgia 30303
(404) 727-6123
Principal Investigator: Srihari Veeraraghavan, M.D
Phone: 404-712-7458
Emory University Emory University, recognized internationally for its outstanding liberal artscolleges, graduate and professional schools,...
?
mi
from
Atlanta, GA
Click here to add this to my saved trials
Sacramento, California 95814
Principal Investigator: Timothy Albertson, M.D.
Phone: 916-734-3560
?
mi
from
Sacramento, CA
Click here to add this to my saved trials
Baltimore, Maryland 20742
(301) 405-1000
Principal Investigator: James Britt, M.D.
Phone: 410-328-1473
University of Maryland As a globally-connected university offering a world-class education, the University of Maryland...
?
mi
from
Baltimore, MD
Click here to add this to my saved trials
Birmingham, Alabama 35233
Principal Investigator: Joao de Andrade, M.D.
Phone: 205-934-6229
?
mi
from
Birmingham, AL
Click here to add this to my saved trials
Boston, Massachusetts 02135
Principal Investigator: Peter LaCamera, M.D.
Phone: 617-789-2078
?
mi
from
Boston, MA
Click here to add this to my saved trials
Chesterfield, Missouri 63017
Principal Investigator: Neil Ettinger, M.D
Phone: 314-576-4501
?
mi
from
Chesterfield, MO
Click here to add this to my saved trials
303 East Superior Street
Chicago, Illinois 60611
Principal Investigator: Rishi Raj, M.D.
Phone: 312-695-2269
?
mi
from
Chicago, IL
Click here to add this to my saved trials
Cincinnati, Ohio
Principal Investigator: Nishant Gupta, M.D
Phone: 513-558-0027
?
mi
from
Cincinnati, OH
Click here to add this to my saved trials
Colchester, Vermont 05446
Principal Investigator: Yolanda Mageto, M.D.
Phone: 802-847-2103
?
mi
from
Colchester, VT
Click here to add this to my saved trials
Concord, New South Wales
Principal Investigator: Elizabeth Veitch, M.D.
Phone: +61297675000
?
mi
from
Concord,
Click here to add this to my saved trials
1801 Inwood Rd
Dallas, Texas 75390
(214) 645-3300
Principal Investigator: John Fitzgerald, M.D.
Phone: 214-645-9730
University of Texas Southwestern Medical Center UT Southwestern is an academic medical center, world-renowned for...
?
mi
from
Dallas, TX
Click here to add this to my saved trials
1400 Jackson St
Denver, Colorado 80206
(303) 388-4461
Principal Investigator: Evans R Fernandez Perez, M.D
Phone: 303-398-1859
National Jewish Health National Jewish Health is known worldwide for treatment of patients with respiratory,...
?
mi
from
Denver, CO
Click here to add this to my saved trials
Detroit, Michigan 48202
Principal Investigator: Krishna Thavarajah, M.D.
Phone: 313-916-3558
?
mi
from
Detroit, MI
Click here to add this to my saved trials
Greensboro, North Carolina 27403
Principal Investigator: Murali Ramaswamy, M.D.
Phone: 336-323-5276
?
mi
from
Greensboro, NC
Click here to add this to my saved trials
3901 Rainbow Blvd
Kansas City, Kansas 66160
(913) 588-5000
Principal Investigator: Mark Hamblin, M.D.
Phone: 913-588-6045
University of Kansas Medical Center The University of Kansas Medical Center serves Kansas through excellence...
?
mi
from
Kansas City, KS
Click here to add this to my saved trials
Kissimmee, Florida 34741
Principal Investigator: Thomas O'Brien, M.D.
Phone: 407-624-4831
?
mi
from
Kissimmee, FL
Click here to add this to my saved trials
Lebanon, Ohio 03756
Principal Investigator: Richard Enelow, M.D.
Phone: 603-650-5533
?
mi
from
Lebanon, OH
Click here to add this to my saved trials
10833 Le Conte Ave
Los Angeles, California 90095
(310) 825-4321
Principal Investigator: John Belperio, M.D.
Phone: 310-794-1999
David Geffen School of Medicine, UCLA In 2002 Mr. David Geffen announced a $200 million...
?
mi
from
Los Angeles, CA
Click here to add this to my saved trials
500 S Preston St
Louisville, Kentucky
(502) 852-5555
Principal Investigator: Rafael Perez, M.D
Phone: 502-852-1358
University of Louisville The University of Louisville is a state supported research university located in...
?
mi
from
Louisville, KY
Click here to add this to my saved trials
2201 West End Ave
Nashville, Tennessee 37232
(615) 322-7311
Principal Investigator: Lisa Lancaster, M.D.
Phone: 615-343-7068
Vanderbilt University Vanderbilt offers undergraduate programs in the liberal arts and sciences, engineering, music, education...
?
mi
from
Nashville, TN
Click here to add this to my saved trials
New Haven, Connecticut 6520
(203) 432-4771
Principal Investigator: Danielle Antin-Ozerkis, M.D.
Phone: 203-785-7324
Yale University Yale's roots can be traced back to the 1640s, when colonial clergymen led...
?
mi
from
New Haven, CT
Click here to add this to my saved trials
630 W 168th St
New York, New York
212-305-2862
Principal Investigator: David Lederer, M.D.
Phone: 212-342-4167
Columbia University Medical Center Situated on a 20-acre campus in Northern Manhattan and accounting for...
?
mi
from
New York, NY
Click here to add this to my saved trials
?
mi
from
Pensacola, FL
Click here to add this to my saved trials
200 Lothrop St
Pittsburgh, Pennsylvania 15213
Principal Investigator: Kevin Gibson, M.D
Phone: 412-692-2149
University of Pittsburgh Medical Center UPMC is one of the leading nonprofit health systems in...
?
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
Portland, Oregon 97232
Principal Investigator: Danielle D Hosmer, M.D.
Phone: 503-413-7945
?
mi
from
Portland, OR
Click here to add this to my saved trials
Salt Lake City, Utah 84108
Principal Investigator: Mary Scholand, M.D.
Phone: 801-581-5864
?
mi
from
Salt Lake City, UT
Click here to add this to my saved trials
Wichita, Kansas 67028
Principal Investigator: Mark Wencel, M.D
Phone: 316-689-9542
?
mi
from
Wichita, KS
Click here to add this to my saved trials